DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083
(WorldNews Canada)

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (`DelMar` and `the Company`), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083). DelMar`s new patent strengthens the Company`s control over the VAL-083 manufacturing process and related controls. DelMar is establishing broad new intellectual property protection around VAL-083, a first-in-class DNA targeting...